| Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells M Ikeda, A Nozaki, K Sugiyama, T Tanaka, A Naganuma, K Tanaka, ... Virus research 66 (1), 51-63, 2000 | 222 | 2000 |
| Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection H Toyoda, K Chayama, F Suzuki, K Sato, T Atarashi, T Watanabe, ... Hepatology 67 (2), 505-513, 2018 | 130 | 2018 |
| Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis K Chayama, F Suzuki, Y Karino, Y Kawakami, K Sato, T Atarashi, ... Journal of gastroenterology 53, 557-565, 2018 | 126 | 2018 |
| Activation of the interferon-inducible 2′-5′-oligoadenylate synthetase gene by hepatitis C virus core protein A Naganuma, A Nozaki, T Tanaka, K Sugiyama, H Takagi, M Mori, ... Journal of Virology 74 (18), 8744-8750, 2000 | 107 | 2000 |
| Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein A Nozaki, M Ikeda, A Naganuma, T Nakamura, M Inudoh, K Tanaka, ... Journal of Biological Chemistry 278 (12), 10162-10173, 2003 | 103 | 2003 |
| An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs HJ Cordell, JJ Fryett, K Ueno, R Darlay, Y Aiba, Y Hitomi, M Kawashima, ... Journal of hepatology 75 (3), 572-581, 2021 | 89 | 2021 |
| Preventive effects of vitamin K on recurrent disease in patients with hepatocellular carcinoma arising from hepatitis C viral infection S Kakizaki, N Sohara, K Sato, H Suzuki, M Yanagisawa, H Nakajima, ... Journal of gastroenterology and hepatology 22 (4), 518-522, 2007 | 88 | 2007 |
| Genome-wide association studies identify PRKCB as a novel genetic susceptibility locus for primary biliary cholangitis in the Japanese population M Kawashima, Y Hitomi, Y Aiba, N Nishida, K Kojima, Y Kawai, ... Human molecular genetics 26 (3), 650-659, 2017 | 76 | 2017 |
| Circulating microRNA profiles in patients with type-1 autoimmune hepatitis K Migita, A Komori, H Kozuru, Y Jiuchi, M Nakamura, M Yasunami, ... PLoS One 10 (11), e0136908, 2015 | 75 | 2015 |
| Zinc is a negative regulator of hepatitis C virus RNA replication K Yuasa, A Naganuma, K Sato, M Ikeda, N Kato, H Takagi, M Mori Liver International 26 (9), 1111-1118, 2006 | 71 | 2006 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 63 | 2022 |
| Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element H Dansako, A Naganuma, T Nakamura, F Ikeda, A Nozaki, N Kato Virus research 97 (1), 17-30, 2003 | 62 | 2003 |
| Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection J Toyota, Y Karino, F Suzuki, F Ikeda, A Ido, K Tanaka, K Takaguchi, ... Journal of gastroenterology 52, 385-395, 2017 | 56 | 2017 |
| Current distribution during galvanic corrosion of carbon steel welded with type-309 stainless steel in NaCl solution K Fushimi, A Naganuma, K Azumi, Y Kawahara Corrosion Science 50 (3), 903-911, 2008 | 56 | 2008 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 51 | 2023 |
| Lenvatinib for hepatocellular carcinoma: a literature review T Hatanaka, A Naganuma, S Kakizaki Pharmaceuticals 14 (1), 36, 2021 | 49 | 2021 |
| Hepatitis C virus quasispecies in cancerous and noncancerous hepatic lesions: the core protein-encoding region. SS Alam, T Nakamura, A Naganuma, A Nozaki, K Nouso, H Shimomura, ... Acta medica Okayama 56 (3), 141-147, 2002 | 48 | 2002 |
| Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: a phase II/III, multicenter, randomized, evaluator‐blinded, active‐controlled trial and a … K Suzuki, R Endo, Y Takikawa, F Moriyasu, Y Aoyagi, H Moriwaki, S Terai, ... Hepatology Research 48 (6), 411-423, 2018 | 43 | 2018 |
| Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with child‐Pugh class a or B liver function in real‐world … T Tanaka, A Hiraoka, T Tada, M Hirooka, K Kariyama, J Tani, M Atsukawa, ... Hepatology Research 52 (9), 773-783, 2022 | 40 | 2022 |
| Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective … Y Maruki, C Morizane, Y Arai, M Ikeda, M Ueno, T Ioka, A Naganuma, ... Journal of Gastroenterology 56, 250-260, 2021 | 40 | 2021 |
